All In Biotech

Drug Trial Radar · NCT02444793

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: Feb 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

24

Actual

Start

May 2015

Primary completion

Sep 2017

Study completion Oct 2017

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.
First posted
May 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • PF-05082566Drug

    Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.

  • KW-0761Drug

    Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLT)Time frame: First 2 Cycles (28 days in each cycle)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UC San Diego Medical Center - La Jolla(Thornton Hospital)

    La Jolla, California

  • University Of California / San Diego Moores Cancer Center

    La Jolla, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Georgetown University

    Washington D.C., District of Columbia

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Henry Ford Hospital Research Pharmacy

    Detroit, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • UNC Cancer Hospital Infusion Pharmacy

    Chapel Hill, North Carolina

  • UNC Hospitals, University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Sanford Cancer Center

    Sioux Falls, South Dakota

  • Sanford Research

    Sioux Falls, South Dakota

  • Sanford USD Medical Center

    Sioux Falls, South Dakota

  • Tennessee Oncology, PLLC

    Gallatin, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • The Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.